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A Randomized Trial of Prenatal n−3 Fatty
Acid Supplementation and Preterm Delivery
Maria Makrides, Ph.D., Karen Best, Ph.D., Lisa Yelland, Ph.D.,
Andrew McPhee, M.B., B.S., Shao Zhou, Ph.D., Julie Quinlivan, M.B., B.S., Ph.D.,
Jodie Dodd, M.B., B.S., Ph.D., Elinor Atkinson, M.B., B.S., Huda Safa, M.B., Ch.B.,
Jacqueline van Dam, M.B., B.S., Nisha Khot, M.B., B.S., Gustaaf Dekker, M.D., Ph.D.,
Monika Skubisz, M.B., B.S., Ph.D., Amanda Anderson, Ph.D.,
Beth Kean, B.Med.Sci., Anneka Bowman, M.Res., Carly McCallum, B.Nutr.Diet.,
Kara Cashman, G.Dip.Stat., and Robert Gibson, Ph.D.

A BS T R AC T
BACKGROUND

Previous studies have suggested that maternal supplementation with n−3 long-chain
polyunsaturated fatty acids may reduce the incidence of preterm delivery but may also
prolong gestation beyond term; however, more data are needed regarding the role of n−3
long-chain polyunsaturated fatty acids in pregnancy.
METHODS

We performed a multicenter, double-blind, randomized trial in which women who were
pregnant with single or multiple fetuses were assigned to receive either fish-oil capsules
that contained 900 mg of n−3 long-chain polyunsaturated fatty acids (n−3 group) or
vegetable-oil capsules that contained trace n−3 long-chain polyunsaturated fatty acids
(control group) daily, beginning before 20 weeks of gestation and continuing to 34 weeks
of gestation or delivery, whichever occurred first. The primary outcome was early preterm
delivery, defined as delivery before 34 completed weeks of gestation. Other pregnancy
and neonatal outcomes were also assessed.
RESULTS

A total of 5544 pregnancies in 5517 women were randomly assigned at six centers in
Australia; 5486 pregnancies were included in the primary analysis. Early preterm delivery
occurred in the case of 61 of 2734 pregnancies (2.2%) in the n−3 group and 55 of 2752
pregnancies (2.0%) in the control group; the between-group difference was not significant (adjusted relative risk, 1.13; 95% confidence interval [CI], 0.79 to 1.63; P = 0.50).
There were no significant differences between the groups in the incidence of interventions in post-term (>41 weeks of gestation) deliveries, in adverse events, or in other
pregnancy or neonatal outcomes, except that a higher percentage of infants born to
women in the n−3 group than in the control group were very large for gestational age at
birth (adjusted relative risk, 1.30; 95% CI, 1.02 to 1.65). Percentages of serious adverse
events did not differ between the groups. Minor gastrointestinal disturbances were more
commonly reported in the n−3 group than in the control group.
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CONCLUSIONS

Supplementation with n−3 long-chain polyunsaturated fatty acids from early pregnancy
(<20 weeks of gestation) until 34 weeks of gestation did not result in a lower incidence
of early preterm delivery or a higher incidence of interventions in post-term deliveries
than control. (Funded by the Australian National Health and Medical Research Council
and the Thyne Reid Foundation; ORIP Australian New Zealand Clinical Trials Registry
number, ACTRN12613001142729.)
n engl j med 381;11
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reterm delivery (defined as delivery
before 37 weeks of gestation) occurs in 15
million pregnancies each year and is the
leading cause of early childhood complications
and death1; early preterm deliveries (defined as
delivery before 34 weeks of gestation) represent
approximately 20% of all preterm deliveries but
account for the largest burden of neonatal deaths
and childhood disability.2 The incidence of preterm deliveries is rising globally,2,3 and although
the drivers for this vary among populations,
identifying an effective, broad-based prevention
strategy is a priority.
Labor initiation in humans is a complex and
incompletely understood interplay of maternal
and fetal endocrine signaling. The balance between oxylipins derived from n−6 arachidonic acid
and those derived from n−3 eicosapentaenoic
acid and docosahexaenoic acid (DHA), which are
also known as n−3 long-chain polyunsaturated
fatty acids, plays an essential role, with proinflammatory 2-series prostaglandins such as PGE2 and
PGF2α known to stimulate cervical ripening and
uterine contractility.4 Typical Western diets are
relatively low in n−3 long-chain polyunsaturated
fatty acids, which leads to a predominance of
2-series prostaglandin substrate in the fetoplacental unit and potentially confers a predisposition to preterm delivery. Epidemiologic studies
have shown significant associations between
lower fish consumption in pregnancy and increased rates of preterm delivery.5-8 The World
Health Organization recommends an intake of
300 mg of n−3 long-chain polyunsaturated fatty
acids per day in pregnant women; however, the
median intake among Australian and American
women of childbearing age is less than one third
of this.9,10 Dietary insufficiency of n−3 longchain polyunsaturated fatty acids may therefore
play a role in the pathophysiology of preterm
delivery and presents a potential target for intervention.
We previously conducted the DOMInO (DHA
to Optimise Mother Infant Outcome) trial, which
showed that DHA had no significant effect on
postpartum depression or infant neurodevelopment (the primary outcomes). In that trial, the
use of DHA resulted in a lower incidence of early
preterm delivery than control, but a higher incidence of post-term (>41 weeks of gestation) deliveries involving obstetrical interventions.11 Both
of those outcomes were secondary and the analy1036
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ses were not adjusted for multiplicity, which limits confidence in these results. Several systematic
reviews have shown inconsistent findings regarding the effect of supplementation with n−3 longchain polyunsaturated fatty acids during pregnancy on early preterm and preterm delivery.12-15
We designed the Omega-3 to Reduce the Incidence
of Preterm Birth (ORIP) trial to assess whether
supplementation with n−3 long-chain polyunsaturated fatty acids, administered from early
pregnancy (<20 weeks of gestation) until 34 weeks
of gestation, would result in a lower incidence of
early preterm delivery than control, without increasing the incidence of post-term obstetrical
interventions, in a broad population of pregnant
women.

Me thods
Trial Design and Oversight

The ORIP trial was designed as a multicenter,
double-blind, randomized, controlled clinical trial
and was funded by the Australian National Health
and Medical Research Council and the Thyne
Reid Foundation. The trial capsules were donated
by Croda UK and Efamol/Wassen UK; neither
company had any other role in the trial. The
funders were not involved in the design of the trial,
the collection or analysis of the data, or the writing of the manuscript. The trial protocol (which
has been published previously16 and is available
with the full text of this article at NEJM.org) was
developed by the authors and was approved by
the human research ethics committee at each trial
center. The trial was conducted according to the
2007 National Statement on Ethical Conduct in
Human Research of the National Health and
Medical Research Council and the Note for Guidance on Good Clinical Practice (CPMP/ICH/135/95).
An independent serious adverse events committee, whose members were unaware of the group
assignments, evaluated adverse outcomes in
mothers and babies. An independent data monitoring committee, whose members had access to
unblinded data related to key trial outcomes
(including the primary outcome), reviewed trial
safety and progress; the committee also reviewed
a planned interim analysis of early preterm delivery halfway through the trial and recommended that the trial continue. The authors analyzed
the data, vouch for the accuracy and completeness of the data and for the fidelity of the trial
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to the protocol, wrote or contributed to the writ- 800 mg of DHA and approximately 100 mg of
ing of the manuscript, and made the decision to eicosapentaenoic acid [Incromega DHA 500TG
submit the manuscript for publication.
capsules]). Patients in the control group received
three 500-mg capsules per day containing an
Participants
isocaloric vegetable-oil blend that provided a
Women who were pregnant with a single fetus total of approximately 15 mg of DHA and apor multiple fetuses and who attended one of six proximately 4 mg of eicosapentaenoic acid per
centers in four states in Australia were recruited day. The assigned capsules were to be taken
at their first antenatal appointment from Novem- orally from the time of trial entry (<20 weeks of
ber 1, 2013, to April 26, 2017. Women were ex- gestation) until 34 weeks of gestation or until
cluded if they were taking daily supplements delivery, whichever occurred sooner. Control
containing more than 150 mg of n−3 long-chain capsules were formulated to be consistent with
polyunsaturated fatty acids or if they were un- the fatty acid composition of a typical Australian
willing to discontinue daily supplements contain- diet. The full compositions of the capsules are
ing 150 mg or less of n−3 long-chain polyunsatu- provided in Table S1 in the Supplementary Aprated fatty acids. Women were also excluded if pendix, available at NEJM.org.
they had coagulopathy, were receiving anticoaguAt the time of enrollment, baseline clinical
lants, had a known history of substance abuse, and sociodemographic characteristics of the paror if their fetus had a known congenital abnor- ticipants were assessed, and a dried blood spot
mality. Women could participate in the trial for for fatty acid analysis was collected on filter
successive pregnancies and underwent a separate paper.17,18 Adherence to the trial regimen and the
randomization for each pregnancy. The last infant occurrence of any adverse events were assessed
was born on November 26, 2017, and data collec- by means of telephone contact 2 weeks after
tion was completed on January 8, 2018.
enrollment and at 28 weeks of gestation. Women
returned for in-person visits at 34 weeks of gesRandomization and Masking
tation so that the number of unused capsules
After written informed consent was obtained, could be recorded and a dried blood spot could
women were randomly assigned, with the use of be obtained. Data were extracted from maternal
a Web-based randomization service, to receive and infant medical records 6 weeks after deliveither n−3 long-chain polyunsaturated fatty acid ery by trained trial staff who were not members
capsules (n−3 group) or vegetable-oil capsules of the clinical care team.
(control group); the randomization schedule was
prepared by an independent statistician, with bal- Outcomes
anced variable blocks and stratification accord- The length of gestation at the time of delivery
ing to trial center and previous use of n−3 long- was determined on the basis of both the date of
chain polyunsaturated fatty acid supplements (yes the last menstrual period and ultrasonographic
or no). At randomization, women were provided data obtained in early pregnancy (the full algowith five bottles, each containing 90 capsules. rithm is provided in Fig. S1 in the SupplemenAdditional capsules were reissued as necessary. tary Appendix). The primary outcome was early
The bottles and capsules of n−3 fatty acid and preterm delivery, defined as delivery before 34
control were identical in appearance, and the con- completed weeks of gestation. Secondary outtrol capsules contained 5% tuna oil to aid in the comes included other pregnancy, delivery, and
masking of the group assignment. Participants, neonatal outcomes (Table S2 in the Supplemenclinicians, and researchers remained unaware of tary Appendix).
the group assignments until the data analysis was
Statistical Analysis
complete.
On the basis of the incidence of early preterm
Trial Interventions
deliveries among singleton pregnancies in a simiWomen in the n−3 group received three 500-mg lar population11 and the higher rates of early
fish-oil capsules per day, which provided a total preterm delivery that are expected among pregof approximately 900 mg of n−3 long-chain poly- nancies with multiple fetuses than among singleunsaturated fatty acid per day (approximately ton pregnancies, and assuming a 5% loss to
n engl j med 381;11
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follow-up, we calculated that 5540 pregnancies
(2770 per group) would be needed to provide the
trial with 85% power to show a rate of early
preterm delivery that was 1.16 percentage points
lower in the n−3 group than in the control group
(1.29% vs. 2.45%), at a two-sided alpha level of
0.049 at the final analysis. A single interim
analysis of the primary outcome was prespecified when the first 2270 deliveries had occurred.
An O’Brien–Fleming alpha spending function was
used to control the type I error rate at 0.05.19
The primary analysis was performed on an
intention-to-treat basis. The incidence of early
preterm delivery was compared between the
groups with the use of a log-binomial regression
model. Adjustment was made for the randomization strata in the primary analysis; unadjusted
analyses were also performed. Generalized estimating equations were used to account for clustering of pregnancies in women who participated
in the trial for successive pregnancies.
Secondary outcomes were compared between
the groups with the use of log-binomial, linear,
and log-Poisson regression models for binary,
continuous, and count outcomes, respectively.
Generalized estimating equations were used in
the assessment of maternal outcomes to account
for clustering of pregnancies in women who
participated in the trial for successive pregnancies and in the assessment of neonatal outcomes
to account for clustering due to siblings (from
the same pregnancy or successive pregnancies).
Time-to-event outcomes were analyzed with the
use of Fine and Gray regression models for competing risks, with a cluster-adjusted variance
estimator.20
Multiple imputation with the use of chained
equations was performed separately in each group
to address missing data under a missing-at-random
assumption.21 Data on outcomes that were undefined because of miscarriage, termination of
pregnancy, or stillbirth were not imputed. Adjusted analyses that used imputed data were
considered to be the primary analyses.
Prespecified analyses of early preterm delivery
and related secondary outcomes (27 outcomes
total) were performed in subgroups defined according to pregnancy with single or multiple
fetuses, history of preterm delivery (yes or no),
and baseline DHA level (in quartiles). Four of the
81 planned interaction tests were expected to be
significant (P<0.05) by chance.
1038
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No adjustment was made for multiple comparisons of outcomes, so P values are reported
only for the primary outcome, serious adverse
events, and interaction tests in subgroup analyses. The 95% confidence intervals reported for
secondary outcomes and subgroup analyses have
not been adjusted for multiplicity and therefore
should not be used to infer treatment effects. All
analyses were performed with the use of SAS
software, version 9.4 (SAS Institute), and followed
a prespecified statistical analysis plan (available
at NEJM.org).

R e sult s
Trial Participants

A total of 5544 pregnancies in 5517 women were
randomly assigned at the six trial centers; 27
women participated in the trial twice and underwent a separate randomization for each pregnancy (for 14 of these women, the group to
which they were assigned the second time was
different from the group to which they had been
assigned the first time). A total of 2770 pregnancies in 2766 women were assigned to the n−3
group, and 2774 pregnancies in 2765 women to
the control group (Fig. 1). After withdrawal of
consent, loss to follow-up, miscarriages, and
terminations of pregnancies, primary outcome
data were available for 5431 pregnancies (98%).
After multiple imputation for missing data, 5486
pregnancies were included in the primary analysis (2734 in the n−3 group and 2752 in the control group).
Baseline characteristics were balanced between the groups (Table 1, and Table S3 in the
Supplementary Appendix). At the end of the intervention period, the mean DHA concentration in
the dried blood spots obtained from women
in the n−3 group was 32% higher than that
among women in the control group (Table S7 in
the Supplementary Appendix).
Outcomes

There was no significant between-group difference in the primary outcome of early preterm
delivery. Early preterm delivery occurred in the
case of 61 of 2734 pregnancies (2.2%) in the n−3
group and 55 of 2752 pregnancies (2.0%) in the
control group (unadjusted and adjusted relative
risk, 1.13; 95% confidence interval [CI], 0.79 to
1.63; P = 0.50).
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34,300 Pregnancies were assessed
for eligibility

18,961 Were ineligible
5346 Involved women who were taking n–3
supplements (>150 mg per day)
4496 Had incomplete screening
4952 Had duration of gestation ≥20 wk
2936 Were in women who did not provide consent
756 Involved women who declined to discontinue
n–3 supplements (≤150 mg per day)
248 Were in women with a history of substance
abuse
174 Were in women with a bleeding disorder or
who were receiving anticoagulant
53 Had known fetal abnormality

15,339 Were confirmed to be eligible

8687 Were in women who declined to participate
1091 Had duration of gestation ≥20 wk before
consent was given
17 Were in women who consented, but gestation
≥20 wk was reached before randomization
5544 Pregnancies in 5517 women
underwent randomization

2770 Pregnancies in 2766 women
were assigned to the n–3 group

2774 Pregnancies in 2765 women
were assigned to the control group
50 Pregnancies in 50 women
did not have outcome
data available
14 Women withdrew consent
22 Women miscarried or
terminated pregnancy
<20 wk
8 Women terminated pregnancy ≥20 wk
6 Women were lost to
follow-up

63 Pregnancies in 63 women
did not have outcome
data available
12 Women withdrew consent
36 Women miscarried or
terminated pregnancy
<20 wk
8 Women terminated pregnancy ≥20 wk
7 Women were lost to
follow-up
2707 Pregnancies in 2704 women
had primary outcome data available

2724 Pregnancies in 2715 women
had primary outcome data available

2734 Pregnancies in 2731 women
were included in the primary analysis
after multiple imputation for missing data

2752 Pregnancies in 2743 women
were included in the primary analysis
after multiple imputation for missing data

Figure 1. Screening, Randomization, and Follow-up.
A total of 27 women participated in the trial twice and underwent a separate randomization for each pregnancy; for
14 of these women, the group to which they were assigned the second time was different from the group to which
they had been assigned the first time. One woman who was assigned to the n−3 group twice withdrew consent for
one pregnancy but provided primary outcome data for the other. Multiple imputation was used for missing data in
the primary analysis, with the exception of miscarriages and terminations before 20 weeks of gestation.
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Table 1. Baseline Characteristics of the Pregnancies.*
n−3 Group
(N = 2770)

Control Group
(N = 2774)

374 (13.5)

368 (13.3)

Median maternal age (IQR) — yr†

30.0 (26.0–34.0)

30.0 (27.0–33.0)

Median gestation (IQR) — wk‡

14.1 (12.7–16.4)

14.1 (12.7–16.6)

Mother was primiparous — no./total no. (%)

1223/2754 (44.4)

1209/2765 (43.7)

52/2698 (1.9)

48/2721 (1.8)

Characteristic
Mother consumed dietary supplements containing n−3 long-chain polyunsaturated
fatty acid in the previous 3 mo — no. (%)

Pregnancy with multiple fetuses — no./total no. (%)
Median maternal weight at trial entry (IQR) — kg§

69.7 (60.9–81.5)

69.0 (60.9–81.0)

Maternal white race — no./total no. (%)¶

2057/2764 (74.4)

2041/2767 (73.8)

Mother completed a high school education — no./total no. (%)

2246/2756 (81.5)

2194/2764 (79.4)

Mother smoked cigarettes at trial entry or leading up to pregnancy — no./total no. (%)
Mother drank alcohol at trial entry or leading up to pregnancy — no./total no. (%)
Mother had previous preterm delivery: <37 wk of gestation — no./total no. (%)
Median maternal DHA level (IQR) — % of total fatty acids‖
Male fetus — no./total no. of fetuses (%)**

435/2755 (15.8)

430/2766 (15.5)

1513/2755 (54.9)

1562/2764 (56.5)

185/2754 (6.7)

184/2766 (6.7)

2.7 (2.3–3.1)

2.7 (2.3–3.1)

1395/2758 (50.6)

1409/2770 (50.9)

*	There were no significant differences between the groups in any baseline characteristics at a two-sided alpha level of 0.05 except for the
number of mothers who completed a high school education (P = 0.047). DHA denotes docosahexaenoic acid, and IQR interquartile range.
†	Data were missing for 1 pregnancy in the control group.
‡	Data were missing for 15 pregnancies in the n−3 group and 7 pregnancies in the control group.
§	Data were missing for 78 pregnancies in the n−3 group and 64 pregnancies in the control group.
¶	Race was reported by the mothers.
‖	Data were missing for 135 pregnancies in the n−3 group and 133 pregnancies in the control group.
**	The total number of fetuses was 2823 in the n−3 group and 2822 in the control group. The total number shown is the total number for
which data were available.

The mean duration of gestation was 273 days in
both groups. There were no significant betweengroup differences in key secondary outcomes,
including maternal outcomes of preterm delivery, post-term interventions of induction of labor
or cesarean section, and spontaneous early preterm delivery and neonatal outcomes of birth
weight, low birth weight (<2500 g), and admission to the neonatal intensive care unit (Tables 2
and 3, and Tables S4 and S5 in the Supplementary Appendix).
Analysis of secondary neonatal outcomes
showed that there was a greater incidence of
infants born very large for gestational age (birth
weight, >97th percentile for corresponding gestational age and sex22) in the n−3 group than in
the control group (adjusted relative risk, 1.30;
95% CI, 1.02 to 1.65) but not a greater incidence
of infants born large for gestational age (birth
weight, >90th percentile for corresponding gestational age and sex) (Table 3).22 The greater incidence of infants born very large for gestational

1040
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age did not correspond to a higher incidence in
the n−3 group of obstetrical interventions such
as cesarean section or post-term induction of
labor, nor to a higher incidence among neonates
in that group of shoulder dystocia or complications related to shoulder dystocia (e.g., admission
to the neonatal intensive care unit of infants
born after 34 weeks of gestation, use of supplemental oxygen, or intraventricular hemorrhage)
(see Table S5 in the Supplementary Appendix).
Results of the prespecified subgroup analyses
are reported in Tables S11 through S13 in the
Supplementary Appendix.
Safety and Side Effects

No significant differences in serious adverse
events were noted between the groups (Table 4).
The percentage of miscarriages (loss of pregnancy before 20 weeks of gestation) was 1.1% in
the n−3 group and 0.6% in the control group. Of
the 32 women in the n−3 group who had a miscarriage, 11 women (34%) had not commenced
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Table 2. Trial Outcomes.*
Outcome
Primary outcome: early preterm delivery — no. (%)

n−3 Group
(N = 2734)

Control Group
(N = 2752)

Unadjusted Effect Size
(95% CI)†

Adjusted Effect Size
(95% CI)†

61 (2.2)

55 (2.0)

1.13 (0.79 to 1.63)‡

1.13 (0.79 to 1.63)‡

211 (7.7)

246 (8.9)

0.86 (0.72 to 1.03)

0.86 (0.72 to 1.03)

28 (1.0)

20 (0.7)

1.44 (0.81 to 2.56)

1.44 (0.81 to 2.57)

Key secondary outcomes
Preterm delivery — no. (%)
Early preterm spontaneous labor — no. (%)
Preterm spontaneous labor — no. (%)

77 (2.8)

95 (3.5)

0.82 (0.60 to 1.10)

0.82 (0.60 to 1.10)

Gestation at delivery — days

273.2±15.2

273.2±14.9

0.02 (−0.78 to 0.82)§

0.02 (−0.78 to 0.82)§

Time to spontaneous labor — days¶

274.8±14.9

275.2±13.2

0.97 (0.90 to 1.05)

0.97 (0.90 to 1.05)

Post-term induction — no. (%)

138 (5.0)

150 (5.5)

0.92 (0.74 to 1.16)

0.92 (0.74 to 1.16)

Clinical indication for post-term induction
— no. (%)

208 (7.6)

191 (7.0)

1.10 (0.91 to 1.32)

1.10 (0.91 to 1.33)

Post-term, prelabor cesarean section — no. (%)

3 (0.1)

5 (0.2)

0.63 (0.15 to 2.58)

Clinical indication for post-term, prelabor
cesarean section — no. (%)‖

1 (<0.1)

0

NA

NA
NA

Post-term induction or post-term, prelabor
cesarean section — no. (%)

141 (5.2)

156 (5.7)

0.91 (0.73 to 1.14)

0.91 (0.73 to 1.14)

Clinical indication for post-term induction
or post-term, prelabor cesarean section
— no. (%)

209 (7.7)

192 (7.0)

1.10 (0.91 to 1.33)

1.10 (0.91 to 1.33)

456 (16.7)

411 (15.0)

1.11 (0.99 to 1.26)

1.11 (0.99 to 1.26)

Prelabor, preterm, premature rupture of
membranes — no. (%)

86 (3.1)

101 (3.7)

0.86 (0.64 to 1.14)

0.85 (0.64 to 1.14)

Prolonged gestation — no. (%)

12 (0.4)

12 (0.4)

1.01 (0.43 to 2.36)

Other secondary outcomes
Prelabor, premature rupture of membranes
— no. (%)

NA

Cesarean section — no. (%)

926 (33.9)

932 (33.9)

1.00 (0.93 to 1.08)

1.00 (0.93 to 1.07)

Gestational diabetes — no. (%)**

439 (16.1)

406 (14.8)

1.09 (0.95 to 1.24)

1.09 (0.95 to 1.24)

96 (3.5)

91 (3.3)

1.07 (0.80 to 1.43)

1.07 (0.80 to 1.43)

398 (14.6)

398 (14.5)

1.01 (0.89 to 1.15)

1.01 (0.88 to 1.14)

69 (2.5)

57 (2.1)

1.21 (0.86 to 1.72)

1.21 (0.86 to 1.72)

Preeclampsia — no. (%)
Postpartum hemorrhage — no. (%)
Post hoc exploratory outcome: shoulder dystocia
— no. (%)

*	Plus–minus values are means ±SD. Missing data, with the exception of miscarriages and terminations before 20 weeks of gestation, were
multiply imputed. Average numerators across the 100 imputed data sets were rounded to the nearest integer, and therefore reported percentages may differ from the expected values. Early preterm was defined as less than 34 weeks of gestation, preterm as less than 37 weeks of
gestation, post-term as more than 41 weeks of gestation, and prolonged gestation as more than 42 weeks of gestation. All outcomes were
prespecified unless otherwise indicated. NA denotes not applicable because of insufficient numbers of events.
†	The effect sizes are relative risks (n−3 group vs. control group) unless otherwise indicated. The adjusted values were adjusted for randomization strata: recruitment hospital and consumption of dietary supplements containing n−3 long-chain polyunsaturated fatty acid in the
previous 3 months (yes or no). Except in the case of the primary outcome, the 95% confidence intervals were not adjusted for multiplicity
and therefore should not be used to infer treatment effects.
‡	P = 0.50.
§	The effect size is the difference in means (n−3 group minus control group).
¶	Data are shown for 1238 pregnancies in the n−3 group and 1275 pregnancies in the control group in which spontaneous labor occurred.
The effect sizes are the subdistribution hazard ratios of spontaneous labor, with induction and prelabor cesarean section treated as competing risks and with data on outcomes for women who withdrew from the trial censored at the time of withdrawal.
‖	No imputation of data was performed because of insufficient numbers of events. Data are shown for 2704 pregnancies in the n−3 group
and 2721 pregnancies in the control group.
**	Gestational diabetes was defined as a baseline blood glucose level of 5.1 mmol or more per liter (92 mg per deciliter), a 1-hour blood glucose level of 10.0 mmol or more per liter (180 mg per deciliter), or a 2-hour blood glucose level of 8.5 mmol or more per liter (153 mg per
deciliter).

n engl j med 381;11

nejm.org

September 12, 2019

1041

The New England Journal of Medicine
Downloaded from nejm.org at UNIVERSITY OF NOTRE DAME AUS on September 30, 2019. For personal use only. No other uses without permission.
Copyright © 2019 Massachusetts Medical Society. All rights reserved.

1042

n engl j med 381;11

nejm.org

2/2735 (0.1)
11/2735 (0.4)
11/2735 (0.4)

Sepsis — no./total no. (%)**

Retinopathy of prematurity — no./total no. (%)**

7/2758 (0.3)

1.58 (0.58 to 4.35)

1.85 (0.68 to 4.99)

NA

1.19 (0.54 to 2.65)

1.01 (0.38 to 2.66)

0.34 (0.03 to 3.23)

1.28 (0.87 to 1.87)

1.11 (0.94 to 1.33)

1.24 (0.92 to 1.68)

−0.03 (−0.15 to 0.08)¶

−0.02 (−0.21 to 0.17)¶

1.29 (1.02 to 1.65)

1.11 (0.97 to 1.27)

1.11 (0.95 to 1.30)

0.83 (0.53 to 1.29)

1.06 (0.87 to 1.28)

1.21 (0.75 to 1.95)

1.18 (0.95 to 1.48)

0.03 (−0.02 to 0.09)¶

10.53 (−23.94 to 45.00)¶

Unadjusted Effect Size
(95% CI)†

NA

NA

NA

1.19 (0.53 to 2.64)

NA

NA

1.27 (0.87 to 1.86)

1.11 (0.94 to 1.33)

1.24 (0.92 to 1.68)

−0.03 (−0.15 to 0.08)¶

−0.02 (−0.21 to 0.17)¶

1.30 (1.02 to 1.65)

1.11 (0.97 to 1.27)

1.11 (0.95 to 1.30)

0.83 (0.54 to 1.29)

1.06 (0.87 to 1.28)

1.21 (0.75 to 1.94)

1.18 (0.95 to 1.47)

0.03 (−0.02 to 0.09)¶

10.56 (−23.87 to 44.99)¶

Adjusted Effect Size
(95% CI)†

of

6/2758 (0.2)

0/2758

11/2758 (0.4)

9/2758 (0.3)

3/2758 (0.1)

56/2779 (2.0)

232/2779 (8.3)

86/2779 (3.1)

34.4±2.0

50.2±3.3

113/2800 (4.0)

355/2800 (12.7)

280/2800 (10.0)

47/2800 (1.7)

196/2800 (7.0)

36/2800 (1.3)

173/2800 (6.2)

0.2±1.0

3340±591

Control Group

n e w e ng l a n d j o u r na l

*	Plus–minus values are means ±SD. All listed outcomes were prespecified. NA denotes not applicable because of insufficient numbers of events.
†	The effect sizes are relative risks (n−3 group vs. control group) unless otherwise indicated. The adjusted effect values were adjusted for randomization strata: recruitment hospital and
consumption of dietary supplements containing n−3 long-chain polyunsaturated fatty acid in the previous 3 months (yes or no). The 95% confidence intervals were not adjusted for
multiplicity and therefore should not be used to infer treatment effects.
‡	The outcome is a key secondary outcome.
§	Missing data, with the exception of miscarriages and terminations before 20 weeks of gestation, were multiply imputed. Average numerators across the 100 imputed data sets were
rounded to the nearest integer, and therefore reported percentages may differ from the expected values. Data are shown for 2787 infants in the n−3 group and 2800 infants in the control group.
¶	The effect size is the difference in means (n−3 group minus control group).
‖	Missing data, with the exception of miscarriages, terminations, and stillbirths, were multiply imputed. Average numerators across the 100 imputed data sets were rounded to the nearest integer.
**	No imputation of data was performed because of insufficient numbers of events.

13/2735 (0.5)

Necrotizing enterocolitis — no./total no. (%)**

1/2735 (<0.1)
9/2735 (0.3)

Neonatal convulsion — no./total no. (%)**

Any brain injury — no./total no. (%)**

Surgery — no./total no. (%)**

71/2763 (2.6)

257/2763 (9.3)

Receipt of supplemental oxygen — no./total no. (%)‖

Intermittent positive-pressure ventilation — no./total no. (%)‖

34.4±2.2
107/2763 (3.9)

Head circumference at birth — cm§

Admission to neonatal intensive care unit — no./total no. (%)‡‖

50.1±3.5

Birth length — cm§

146/2787 (5.2)

392/2787 (14.1)

Large for gestational age: >90th percentile — no./total no. (%)§

Very large for gestational age: >97th percentile — no./total no. (%)§

39/2787 (1.4)
310/2787 (11.1)

High birth weight: >4000 g — no./total no. (%)§

Small for gestational age: <10th percentile — no./total no. (%)§

Very small for gestational age: <3rd percentile — no./total no. (%)§

43/2787 (1.6)
206/2787 (7.4)

Very low birth weight: <1500 g — no./total no. (%)§

204/2787 (7.3)

Low birth weight: <2500 g — no./total no. (%)‡§

0.2±1.1

3351±628

Birth weight — g‡§

Birth-weight z score‡§

n−3 Group

Outcome

Table 3. Secondary Clinical Outcomes in Infants.*
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Table 4. Serious Adverse Events.*
Variable

n−3 Group

Control Group

2734

2752

Unadjusted Relative
Risk (95% CI)†

P Value

Maternal outcomes‡
No. of pregnancies
Death — no. (%)

0

0

Admission to the intensive care unit — no. (%)

14 (0.5)

10 (0.4)

1.41 (0.63–3.17)

0.41

Any serious adverse event — no. (%)

14 (0.5)

10 (0.4)

1.41 (0.63–3.17)

0.41

Neonatal or pregnancy outcomes
No. of fetuses or infants

2823

2822

Admission of infants born >34 wk of gestation to the neonatal
intensive care unit — no. (%)

58 (2.1)

50 (1.8)

1.16 (0.79–1.70)

0.45

Perinatal death — no. (%)§

32 (1.1)

25 (0.9)

1.28 (0.76–2.17)

0.36

Stillbirth — no. (%)

16 (0.6)

13 (0.5)

1.23 (0.59–2.55)

0.58

Termination of pregnancy <20 wk of gestation — no. (%)

4 (0.1)

4 (0.1)

1.00 (0.25–3.99)

1.00

Termination of pregnancy ≥20 wk of gestation — no. (%)

8 (0.3)

8 (0.3)

1.00 (0.38–2.66)

1.00

8 (0.3)

4 (0.1)

2.00 (0.60–6.63)

0.26

30 (1.1)

25 (0.9)

1.20 (0.71–2.03)

0.50

32 (1.1)

18 (0.6)

1.78 (1.00–3.16)

0.05

142 (5.0)

112 (4.0)

1.27 (0.99–1.62)

0.06

Neonatal death — no. (%)
Major congenital abnormality — no. (%)
Miscarriage <20 wk of gestation — no. (%)
Any serious adverse event in an infant or related to the pregnancy — no. (%)

*	All listed outcomes were prespecified secondary outcomes that were considered serious adverse events.
†	The 95% confidence intervals were not adjusted for multiplicity and therefore should not be used to infer treatment effects.
‡	Pregnancies that resulted in miscarriage or termination before 20 weeks of gestation were excluded from the analysis of maternal outcomes.
§	The outcome is a key secondary outcome.

taking their capsules, and 21 (66%) had consumed capsules for a mean of 13 days before the
miscarriage.
Differences between the groups were observed
in side effects, particularly gastrointestinal side
effects; women in the n−3 group were more
likely to report burping than women in the control group — an effect that is commonly reported in fish-oil supplementation studies.11 Our
addition of a trace quantity of tuna oil to the
control capsules was unsuccessful in masking
group assignment, since more women in the n−3
group than in the control group were able to
correctly guess their assigned intervention. Maternal reports of diarrhea at 28 weeks of gestation and constipation overall were slightly higher
in the n−3 group than in the control group (Tables S6 and S7 in the Supplementary Appendix).

acids from approximately 14 weeks of gestation
until 34 weeks of gestation did not have a lower
risk of early preterm delivery (delivery before 34
weeks of gestation) or preterm delivery (delivery
before 37 weeks of gestation) than women in the
control group. The incidences of post-term induction and cesarean section were not significantly higher in the n−3 group than in the control group. Overall, the duration of gestation
was similar in the two groups. Maternal and
neonatal outcomes did not differ between the
groups except that more babies born to women
in the n−3 group than in the control group were
very large for gestational age at birth; this was
one of multiple secondary outcomes assessed,
and adjustment was not made for multiplicity.
This trial was designed with the primary aim
of confirming the secondary observation in our
earlier DOMInO trial that suggested that supplementation with n−3 long-chain polyunsaturated
Discussion
fatty acids during pregnancy reduced the risk of
We found that women who received supplemen- early preterm delivery.11 We ceased supplementatation with n−3 long-chain polyunsaturated fatty tion at 34 weeks of gestation, since the results
n engl j med 381;11
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of the DOMInO trial also suggested that supplementation with n−3 long-chain polyunsaturated
fatty acids until delivery increased the risk of
post-term obstetrical intervention.11 Pregnancy
outcomes in the DOMInO trial were secondary
outcomes, and results were not adjusted for multiple comparisons and may have been chance
findings. The results of the current ORIP trial do
not support our earlier results in the DOMInO
trial and also contrast with findings in other
trials23,24 and with the most recent Cochrane
systematic review.25 Many previous studies were
designed to assess n−3 long-chain polyunsaturated fatty acid supplementation in specific pregnancy populations or were designed with childhood allergy or childhood neurodevelopment as
primary outcomes. The ORIP trial was designed
to assess duration of gestation, it had few exclusion criteria related to prematurity risk, and it
started supplementation earlier in pregnancy
than the previous studies.
The overall reported adherence among patients
in the n−3 group in this trial in mid-to-late pregnancy was lower than that in the DOMInO trial.11
Nevertheless, the overall increase in the percentage of whole-blood DHA and eicosapentaenoic
acid as total fatty acids and the associated reduction in arachidonic acid were the expected biochemical responses to n−3 long-chain polyunsaturated fatty acid supplementation, and restricting
the analysis to women who adhered to the protocol did not alter the conclusions.
The baseline level of n−3 long-chain polyunsaturated fatty acids in the women in this trial
may have been higher than that in previous
studies, and this may have contributed to the
absence of appreciable effects of supplementation on outcomes. Approximately 80% of Australian women now consume perinatal supplements,
many of which contain small doses of DHA.26
Although we excluded women who were taking
more than 150 mg of DHA per day, we enrolled
more than 700 women who were known to have
been regularly consuming a low dose of DHA
(≤150 mg per day). This may have influenced the
baseline level of DHA among the women included
in the ORIP trial, which was about 20% higher
than that observed in the Kansas University DHA
Outcomes Study (KUDOS), in which a significantly lower rate of early preterm delivery was
observed with n−3 supplementation than with
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placebo.23 The results of subgroup analyses in
one of the few other trials to assess baseline n−3
intake suggested that the prolongation of pregnancy with n−3 long-chain polyunsaturated fatty
acid supplementation was most evident among
women with the lowest intakes, although the
interaction test did not reach significance.27 It is
possible that women with low n−3 status are the
ones most likely to benefit from dietary supplementation strategies; however, we did not find
evidence to support this hypothesis in the prespecified subgroup analysis we performed according to baseline DHA status. Further study is
needed to determine whether there may be benefit
in women who have low n−3 levels.
Our observation of a higher incidence in the
n−3 group than in the control group of infants
(primarily in singleton pregnancies) who were
very large for gestational age adds to the debate
of whether n−3 long-chain polyunsaturated fatty
acid supplementation directly influences fetal
growth.24,25,28 In the absence of clear evidence of
change in other measures of infant anthropometry, and given the large number of outcomes
assessed (without adjustment for multiplicity), this
result may be a chance finding.
In conclusion, in this large, randomized trial
with broad inclusion criteria, n−3 supplementation in pregnancy did not result in a lower risk
of early preterm delivery than control.
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